Literature DB >> 33634011

Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric Cancer Patients.

Jia Wei1, Xiaofeng Lu2, Qin Liu1, Lin Li3, Song Liu4, Fangcen Liu3, Yao Fu3, Xiangshan Fan3, Yang Yang1, Chuang Qi5, Yangyang Yu5, Wenxian Guan2, Baorui Liu1.   

Abstract

Programmed death 1(PD-1) blockade has shown promising efficacy in advanced gastric cancer. Here, we performed a retrospective analysis of three patients with locally advanced gastric cancer who received adjuvant PD-1 plus chemoradiotherapy as neoadjuvant treatment. Neoadjuvant sintilimab plus concurrent chemoradiotherapy had an acceptable side-effect profile. All three patients underwent surgical gastrectomy after a median of 3.9 months. A major pathological response occurred in two resected tumors and a pathologic complete response was observed in one patient. Our results suggest that PD-1 blockade combined with chemoradiotherapy is a promising strategy as a neoadjuvant therapy in patients with unresectable locally advanced gastric cancer.
Copyright © 2021 Wei, Lu, Liu, Li, Liu, Liu, Fu, Fan, Yang, Qi, Yu, Guan and Liu.

Entities:  

Keywords:  PD-1 inhibitor; chemoradiotherapy; immune microenvironment; locally advanced gastric cancer; neoadjuvant

Year:  2021        PMID： 33634011      PMCID： PMC7901487          DOI： 10.3389/fonc.2020.554040

Source DB:  PubMed          Journal:  Front Oncol        ISSN： 2234-943X            Impact factor:   6.244


  18 in total

1.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

Review 2.  Current status of immune checkpoint inhibition in early-stage NSCLC.

Authors:  J Vansteenkiste; E Wauters; B Reymen; C J Ackermann; S Peters; D De Ruysscher
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

3.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Authors:  Pei-Ling Chen; Whijae Roh; Alexandre Reuben; Zachary A Cooper; Christine N Spencer; Peter A Prieto; John P Miller; Roland L Bassett; Vancheswaran Gopalakrishnan; Khalida Wani; Mariana Petaccia De Macedo; Jacob L Austin-Breneman; Hong Jiang; Qing Chang; Sangeetha M Reddy; Wei-Shen Chen; Michael T Tetzlaff; Russell J Broaddus; Michael A Davies; Jeffrey E Gershenwald; Lauren Haydu; Alexander J Lazar; Sapna P Patel; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Scott E Woodman; Luis M Vence; Ignacio I Wistuba; Rodabe N Amaria; Lawrence N Kwong; Victor Prieto; R Eric Davis; Wencai Ma; Willem W Overwijk; Arlene H Sharpe; Jianhua Hu; P Andrew Futreal; Jorge Blando; Padmanee Sharma; James P Allison; Lynda Chin; Jennifer A Wargo
Journal:  Cancer Discov       Date:  2016-06-14       Impact factor: 39.397

4.  PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Hallie Wimberly; Jason R Brown; Kurt Schalper; Herbert Haack; Matthew R Silver; Christian Nixon; Veerle Bossuyt; Lajos Pusztai; Donald R Lannin; David L Rimm
Journal:  Cancer Immunol Res       Date:  2014-12-19       Impact factor: 11.151

5.  Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.

Authors:  Emanuela Romano; Monika Kusio-Kobialka; Periklis G Foukas; Petra Baumgaertner; Christiane Meyer; Pierluigi Ballabeni; Olivier Michielin; Benjamin Weide; Pedro Romero; Daniel E Speiser
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

Review 6.  Current status of immune checkpoint inhibitors for gastric cancer.

Authors:  Koji Kono; Shotaro Nakajima; Kosaku Mimura
Journal:  Gastric Cancer       Date:  2020-05-28       Impact factor: 7.370

7.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 8.  Tumour-associated macrophages as treatment targets in oncology.

Authors:  Alberto Mantovani; Federica Marchesi; Alberto Malesci; Luigi Laghi; Paola Allavena
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

9.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 10.  Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity.

Authors:  Barbara Seliger
Journal:  Front Immunol       Date:  2019-05-22       Impact factor: 7.561
View more
  2 in total

1.  Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer.

Authors:  Changchang Lu; Yahui Zhu; Weiwei Kong; Ju Yang; Linxi Zhu; Lei Wang; Min Tang; Jun Chen; Qi Li; Jian He; Aimei Li; Xin Qiu; Qing Gu; Dongsheng Chen; Fanyan Meng; Baorui Liu; Yudong Qiu; Juan Du
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

2.  Case report: Two PD-L1 positive unresectable advanced pancreatic carcinoma patients with microsatellite stability achieved R0 resection after PD-1 antibody plus chemotherapy as a successful downstaging therapy: A report of two cases.

Authors:  Lin Shang; Peng Li; Jie Fan; Chunning Zhao; Xiangying Niu; Qitian Bian; Zhilin Yuan; Yanlong Kong; Tingshun Zhu; Bin Xu; Jianxin Dong; Hongjun Xiang
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.